Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
暂无分享,去创建一个
Xuping Xie | P. Shi | Yi-Min Zheng | Shan-Lu Liu | Chaitanya Kurhade | C. Zeng | P. Qu | J. P. Evans | Kai Xu | John P. Evans
[1] J. Chan,et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2 , 2022, Emerging microbes & infections.
[2] Qian Wang,et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.
[3] D. Barouch,et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.
[4] G. Lozanski,et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, The New England journal of medicine.
[5] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[6] Lihua Gao,et al. Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y , 2022, Biology direct.
[7] G. Lozanski,et al. Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, bioRxiv.
[8] Vineet D. Menachery,et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant , 2022, Cell Reports.
[9] T. Zhou,et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2 , 2022, Cell Host & Microbe.
[10] J. Gohda,et al. SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways , 2022, bioRxiv.
[11] D. Barouch,et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.
[12] J. Dushoff,et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.
[13] H. Ullum,et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection , 2022, medRxiv.
[14] H. Mo,et al. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants , 2022, bioRxiv.
[15] Ruhong Yan,et al. Omicron adopts a different strategy from Delta and other variants to adapt to host , 2022, Signal Transduction and Targeted Therapy.
[16] K. Swanson,et al. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 , 2022, Cell Host & Microbe.
[17] Frances E. Muldoon,et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.
[18] S. Rowland-Jones,et al. Omicron entry route , 2022, Nature Reviews Immunology.
[19] Larissa B. Thackray,et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters , 2022, Nature.
[20] S. Vermund,et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.
[21] Y. Kawaoka,et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters , 2022, bioRxiv.
[22] Nan Wang,et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron , 2022, Cell.
[23] N. Krogan,et al. Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission , 2022, Cell Host & Microbe.
[24] C. Riou,et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose , 2022, The Lancet.
[25] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.
[26] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[27] Jordan J. Clark,et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.
[28] P. Maes,et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.
[29] T. Zhou,et al. Neutralization and Stability of SARS-CoV-2 Omicron Variant , 2021, bioRxiv.
[30] Liyuan Liu,et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.
[31] Y. Kawaoka,et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation , 2021, Nature.
[32] H. Mouquet,et al. SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation , 2021, The EMBO journal.
[33] S. Bhatt,et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.
[34] M. Giacca,et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.
[35] D. O’Connor,et al. Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck , 2021, PLoS pathogens.
[36] Vineet D. Menachery,et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.
[37] R. Rottier,et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site , 2021, eLife.
[38] B. Haynes,et al. D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction , 2020, Cell Reports.
[39] G. Lozanski,et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors , 2020, JCI insight.
[40] D. A. Stein,et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells , 2020, Life Science Alliance.
[41] Shinji Makino,et al. An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.
[42] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[43] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[44] J. Luban. SARS-CoV-2 , 2020 .